B. Mei

发表

Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

J. Dumont, S. Estes, R. Kshirsagar, 2015, Critical reviews in biotechnology.

Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.

J. Dumont, Mingxuan Zhang, R. Kshirsagar, 2015, Biologicals : journal of the International Association of Biological Standardization.

This information is current as Bax Apoptosis in Association with Suppression of 1-Phosphate Protection of T Cells from Lysophosphatidic Acid and Sphingosine

E. Goetzl, B. Mei, Y. Kong, 1999 .

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

K. Pasi, T. Lissitchkov, M. Ragni, 2021, Journal of thrombosis and haemostasis : JTH.

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020 .

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity

G. Toby, J. Sommer, G. Pierce, 2014, PloS one.

Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study

T. Matsushita, K. Nogami, M. Taki, 2016 .

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

M. Ozelo, C. Négrier, A. Shapiro, 2015, British journal of haematology.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.

J. Oldenburg, D. Perry, M. Ozelo, 2016, Thrombosis and haemostasis.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia

J. Oldenburg, D. Perry, M. Ozelo, 2017 .

Japanese subject subpopulation analysis of B-LONG: a Phase 3 study of long-acting recombinant factor IX Fc fusion protein

T. Matsushita, M. Taki, M. Shima, 2015 .

Post hoc analysis to evaluate the effect of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in adults and adolescents with target joints and hemophilia B

K. Pasi, R. Liesner, N. Jain, 2016 .

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

John E. Murphy, C. Pan, H. Tjandra, 2010, Blood.

Expression of human coagulation factor VIII in a human hybrid cell line, HKB11

John E. Murphy, C. Pan, B. Mei, 2006, Molecular biotechnology.

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

L. Frenzel, O. Stasyshyn, S. Pipe, 2021, Blood.

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

C. Négrier, S. Pipe, M. Ragni, 2019, Blood.

Lectin Binding Assays for In-Process Monitoring of Sialylation in Protein Production

John E. Murphy, B. Mei, G. Yamasaki, 2010, Molecular biotechnology.

Subject-Reported Changes in Physical Activity During The B-LONG Study of Recombinant Factor IX FC Fusion Protein (RFIXFC) For Severe Haemophilia B

M. Ozelo, M. Ragni, J. Windyga, 2015 .

Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs

John E. Murphy, D. Lillicrap, A. Labelle, 2008 .

Versatile Expression System for Rapid and Stable Production of Recombinant Proteins

H. Yee, C. Mirenda, B. Mei, 2003, Biotechnology progress.

Monomeric Fc‐Fusion Proteins

J. Dumont, S. Krassova, G. Pierce, 2013 .

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020, Blood.

Antifibrotic effects of a tissue inhibitor of metalloproteinase‐1 antibody on established liver fibrosis in rats

Christopher J. Parsons, Barbara Krebs, D. Brenner, 2004, Hepatology.

Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax.

E. Goetzl, B. Mei, Y. Kong, 1999, Journal of immunology.

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.

L. Frenzel, O. Stasyshyn, S. Pipe, 2023, The Lancet. Haematology.

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

G. Young, S. Rangarajan, C. Ross, 2023, The Lancet.

Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)

R. Wu, G. Young, S. Rangarajan, 2021, Blood.